MEI Pharma, Inc. (MEIP): Price and Financial Metrics


MEI Pharma, Inc. (MEIP): $3.29

0.09 (+2.81%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

MEIP POWR Grades


  • Value is the dimension where MEIP ranks best; there it ranks ahead of 87.4% of US stocks.
  • The strongest trend for MEIP is in Growth, which has been heading down over the past 31 weeks.
  • MEIP's current lowest rank is in the Momentum metric (where it is better than 9.33% of US stocks).

MEIP Stock Summary

  • The ratio of debt to operating expenses for MEI Pharma Inc is higher than it is for about just 12.48% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, MEI Pharma Inc is reporting a growth rate of 158.64%; that's higher than 88.99% of US stocks.
  • Revenue growth over the past 12 months for MEI Pharma Inc comes in at 801.59%, a number that bests 98.94% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to MEIP, based on their financial statements, market capitalization, and price volatility, are RCUS, QURE, RKDA, ASMB, and ZGNX.
  • Visit MEIP's SEC page to see the company's official filings. To visit the company's web site, go to www.meipharma.com.

MEIP Price Target

For more insight on analysts targets of MEIP, see our MEIP price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.67 Average Broker Recommendation 1.39 (Strong Buy)

MEIP Stock Price Chart Interactive Chart >

Price chart for MEIP

MEIP Price/Volume Stats

Current price $3.29 52-week high $4.57
Prev. close $3.20 52-week low $2.29
Day low $3.19 Volume 453,700
Day high $3.29 Avg. volume 829,134
50-day MA $3.22 Dividend yield N/A
200-day MA $3.16 Market Cap 370.43M

MEI Pharma, Inc. (MEIP) Company Bio


MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company was founded in 2000 and is based in San Diego, California.


MEIP Latest News Stream


Event/Time News Detail
Loading, please wait...

MEIP Latest Social Stream


Loading social stream, please wait...

View Full MEIP Social Stream

Latest MEIP News From Around the Web

Below are the latest news stories about MEI Pharma Inc that investors may wish to consider to help them evaluate MEIP as an investment opportunity.

MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that utilizes the latest biotechnology to discover and deliver novel medicines, today announced clinical data from a Phase 1b study of zandelisib, an investigational selective phosphatidylinositol 3-kinase delta ("PI3K") inhibitor in clinical development for the treatment of B-cell maligna

Yahoo | June 9, 2021

MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that strives to create new value through the pursuit of advances in life sciences and technologies, today announced the dosing of the first patient with relapsed or refractory marginal zone lymphoma enrolled in the recently added second arm of the global Phase 2 TIDAL study of zandelisib,

Yahoo | June 7, 2021

MEI Pharma to Host Investor and Analyst Video Webcast Event Following 2021 ASCO Annual Meeting

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced it will host an investor and analyst video webcast event on Thursday, June 10, 2021 at 12:00 PM ET following the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The event will include a review of the zandelisib program, including recent data presented at ASCO, and commentary from key opinion leader Deepa Jagadeesh, M.D., MPH, a board-certified medi

Yahoo | June 4, 2021

MEI releases promising phase 1 data on zandelisib for malignancies, lymphoma

MEI Pharm (MEIP) says that new data from two phase 1 trials of its phosphatidylinositol 3-kinase delta ("PI3Kδ") inhibitor zandelisib showed strong response rates in lymphoma and malignancies.In one of the studies, all patients with relapsed/refractory indolent B-cell malignancies and chronic lymphocytic leukemia who received zandelisib combined with BeiGene's BRUKINSA (zanubrutinib)...

Seeking Alpha | May 21, 2021

MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company that utilizes the latest biotechnology to discover and deliver novel medicines, today announced new data for zandelisib, an investigational phosphatidylinositol 3-kinase delta ("PI3Kδ") inhibitor in clinical development for the treatment of B-cell malignancies. The research and the design of a Phase 3 study will be presented in three posters at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021 being held virtually June 4-8, 2021.

Yahoo | May 19, 2021

Read More 'MEIP' Stories Here

MEIP Price Returns

1-mo 26.78%
3-mo -14.10%
6-mo 13.64%
1-year -5.73%
3-year -25.73%
5-year 143.70%
YTD 24.62%
2020 6.45%
2019 -6.06%
2018 25.71%
2017 45.83%
2016 -10.00%

Continue Researching MEIP

Want to see what other sources are saying about MEI Pharma Inc's financials and stock price? Try the links below:

MEI Pharma Inc (MEIP) Stock Price | Nasdaq
MEI Pharma Inc (MEIP) Stock Quote, History and News - Yahoo Finance
MEI Pharma Inc (MEIP) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8151 seconds.